GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » YoY Rev. per Sh. Growth

Can Fite Biofarma (Can Fite Biofarma) YoY Rev. per Sh. Growth

: -56.94% (As of Dec. 2023)
View and export this data going back to 2012. Start your Free Trial

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Can Fite Biofarma's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was -56.94%.

Can Fite Biofarma's Revenue per Share for the three months ended in Dec. 2023 was $0.03.


Can Fite Biofarma YoY Rev. per Sh. Growth Historical Data

The historical data trend for Can Fite Biofarma's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.82 -91.02 -27.43 -35.64 -41.61

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY Rev. per Sh. Growth Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.74 -33.33 -36.00 -36.00 -56.94

Can Fite Biofarma YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Can Fite Biofarma's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.174-0.298)/ | 0.298 |
=-41.61 %

Can Fite Biofarma's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(0.031-0.072)/ | 0.072 |
=-56.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Can Fite Biofarma YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019